ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells

Yuan,Shao; Lei,Shi; Wu,Shengli

doi:10.3892/or.2013.2650

ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells

Authors:
- Shao Yuan
- Shi Lei
- Shengli Wu
View Affiliations

Affiliations: Department of Otorhinolaryngology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: August 2, 2013 https://doi.org/10.3892/or.2013.2650
Pages: 1715-1722

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The overexpression of A disintegrin and metalloproteinase 10 (ADAM10) has been found to be closely associated with the development and progression of various types of tumors. However, ADAM10 expression in hepatocellular carcinoma (HCC) and its significance remain largely unknown. The present study aimed to investigate the expression of ADAM10 in human HCC and the effect of ADAM10 gene silencing by siRNA on the proliferation, invasion and migration of HepG2 human hepatoma cells. Immunohistochemistry was performed to examine the expression of ADAM10 in human HCC tissues and in the adjacent non-cancer tissues from 30 patients with HCC. RNA interference was used to knock down ADAM10 expression in HepG2 human hepatoma cells and the proliferation and migration as well as the invasive ability of the treated cells were observed in vitro. The expression of ADAM10 protein in HCC tissues was significantly higher when compared to that in adjacent non-tumor tissues (P<0.05). The high expression of ADAM10 in cancer was significantly correlated with clinical outcomes (P<0.05). Silencing of ADAM10 resulted in inhibition of proliferation and migration as well as invasion of HepG2 human hepatoma cells (P<0.05). These studies suggest that ADAM10 plays an important role in regulating proliferation, invasion and migration of HepG2 cells. High expression of ADAM10 may be a valuable predictive factor for HCC prognosis, and ADAM10 is potentially an important therapeutic target for the prevention of tumor development and progression in HCC.

View Figures

View References

1	El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
2	Bruix J and Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI
3	Wang N, Feng Y, Lau EP, et al: F-actin reorganization and inactivation of rho signaling pathway involved in the inhibitory effect of Coptidis Rhizoma on hepatoma cell migration. Integr Cancer Ther. 9:354–364. 2010. View Article : Google Scholar : PubMed/NCBI
4	Kanai T, Hirohashi S, Upton MP, et al: Pathology of small hepatocellular carcinoma. A proposal for a new gross classification. Cancer. 60:810–819. 1987. View Article : Google Scholar : PubMed/NCBI
5	Saftig P and Reiss K: The ‘A Disintegrin And Metalloproteases’ ADAM10 and ADAM17: novel drug targets with therapeutic potential? Eur J Cell Biol. 90:527–535. 2011.
6	Crawford HC, Dempsey PJ, Brown G, Adam L and Moss ML: ADAM10 as a therapeutic target for cancer and inflammation. Curr Pharm Des. 15:2288–2299. 2009. View Article : Google Scholar : PubMed/NCBI
7	Postina R, Schroeder A, Dewachter I, et al: A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest. 113:1456–1464. 2004. View Article : Google Scholar
8	Naus S, Blanchet MR, Gossens K, Zaph C, Bartsch JW, McNagny KM and Ziltener HJ: The metalloprotease-disintegrin ADAM8 is essential for the development of experimental asthma. Am J Respir Crit Care Med. 181:1318–1328. 2010. View Article : Google Scholar : PubMed/NCBI
9	Murphy G: The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer. 8:929–941. 2008. View Article : Google Scholar : PubMed/NCBI
10	Lu X, Lu D, Scully M and Kakkar V: ADAM proteins - therapeutic potential in cancer. Curr Cancer Drug Targets. 8:720–732. 2008. View Article : Google Scholar : PubMed/NCBI
11	Becherer JD and Blobel CP: Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). Curr Top Dev Biol. 54:101–123. 2003. View Article : Google Scholar : PubMed/NCBI
12	Huang J, Bridges LC and White JM: Selective modulation of integrin-mediated cell migration by distinct ADAM family members. Mol Biol Cell. 16:4982–4991. 2005. View Article : Google Scholar : PubMed/NCBI
13	Doberstein K, Pfeilschifter J and Gutwein P: The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma. Carcinogenesis. 32:1713–1723. 2011. View Article : Google Scholar : PubMed/NCBI
14	Gaida MM, Haag N, Günther F, et al: Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma. Int J Mol Med. 26:281–288. 2010.PubMed/NCBI
15	Guo J, He L, Yuan P, et al: ADAM10 overexpression in human non-small cell lung cancer correlates with cell migration and invasion through the activation of the Notch1 signaling pathway. Oncol Rep. 28:1709–1718. 2012.PubMed/NCBI
16	Wang YY, Ye ZY, Li L, Zhao ZS, Shao QS and Tao HQ: ADAM 10 is associated with gastric cancer progression and prognosis of patients. J Surg Oncol. 103:116–123. 2011. View Article : Google Scholar : PubMed/NCBI
17	Ko SY, Lin SC, Wong YK, Liu CJ, Chang KW and Liu TY: Increase of disintergin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma. Cancer Lett. 245:33–43. 2007. View Article : Google Scholar : PubMed/NCBI
18	Lee SB, Schramme A, Doberstein K, et al: ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. J Invest Dermatol. 130:763–773. 2010. View Article : Google Scholar : PubMed/NCBI
19	Turner SL, Blair-Zajdel ME and Bunning RA: ADAMs and ADAMTSs in cancer. Br J Biomed Sci. 66:117–128. 2009.PubMed/NCBI
20	Pawlik TM, Gleisner AL, Anders RA, Assumpcao L, Maley W and Choti MA: Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg. 245:435–442. 2007. View Article : Google Scholar
21	Okuda K, Ohtsuki T, Obata H, et al: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 56:918–928. 1985. View Article : Google Scholar : PubMed/NCBI
22	Yu Y, Chen W, Zhang Y, Hamburger AW, Pan H and Zhang Z: Suppression of salivary adenoid cystic carcinoma growth and metastasis by ErbB3 binding protein Ebp1 gene transfer. Int J Cancer. 120:1909–1913. 2007. View Article : Google Scholar : PubMed/NCBI
23	Xu Q, Liu X, Chen W and Zhang Z: Inhibiting adenoid cystic carcinoma cell growth and metastasis by blocking the expression of ADAM 10 using RNA interference. J Transl Med. 8:1362010. View Article : Google Scholar : PubMed/NCBI
24	Llovet JM, Schwartz M and Mazzaferro V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 25:181–200. 2005. View Article : Google Scholar : PubMed/NCBI
25	Zhu W, Owusu L, Zang S, Zhang Y, Xin Y and Yan C: GRP78 and GAL3, differentially regulated by lymph node homogenates, as potential biomarkers for lymph node metastasis in mouse hepatocellular carcinoma cells. Oncol Lett. 4:1374–1378. 2012.PubMed/NCBI
26	Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T and Ben-Ze’ev A: L1, a novel target of β-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol. 168:633–642. 2005.
27	Arima T, Enokida H, Kubo H, et al: Nuclear translocation of ADAM-10 contributes to the pathogenesis and progression of human prostate cancer. Cancer Sci. 98:1720–1726. 2007. View Article : Google Scholar : PubMed/NCBI
28	Jorissen E, Prox J, Bernreuther C, et al: The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J Neurosci. 30:4833–4844. 2010. View Article : Google Scholar : PubMed/NCBI
29	Jacobsen KT, Adlerz L, Multhaup G and Iverfeldt K: Insulin-like growth factor-1 (IGF-1)-induced processing of amyloid-β precursor protein (APP) and APP-like protein 2 is mediated by different metalloproteinases. J Biol Chem. 285:10223–10231. 2010.
30	Venkataramani V, Rossner C, Iffland L, et al: Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. J Biol Chem. 285:10678–10689. 2010. View Article : Google Scholar : PubMed/NCBI
31	Fan X, Liu Y, Jiang J, et al: miR-20a promotes proliferation and invasion by targeting APP in human ovarian cancer cells. Acta Biochim Biophys Sin. 42:318–324. 2010. View Article : Google Scholar : PubMed/NCBI
32	Pan Y, Han C, Wang C, et al: ADAM10 promotes pituitary adenoma cell migration by regulating cleavage of CD44 and L1. J Mol Endocrinol. 49:21–33. 2012. View Article : Google Scholar : PubMed/NCBI
33	Anderegg U, Eichenberg T, Parthaune T, et al: ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells. J Invest Dermatol. 129:1471–1482. 2009. View Article : Google Scholar : PubMed/NCBI
34	DeCicco-Skinner KL, Nolan SJ, Deshpande MM, Trovato EL, Dempsey TA and Wiest JS: Altered prostanoid signaling contributes to increased skin tumorigenesis in Tpl2 knockout mice. PLoS One. 8:e562122013. View Article : Google Scholar : PubMed/NCBI
35	Massi D, Tarantini F, Franchi A, et al: Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Mod Pathol. 19:246–254. 2006. View Article : Google Scholar : PubMed/NCBI
36	Gutwein P, Oleszewski M, Mechtersheimer S, Agmon-Levin N, Krauss K and Altevogt P: Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells. J Biol Chem. 275:15490–15497. 2000. View Article : Google Scholar : PubMed/NCBI